title: Clinical outcome after saphenous vein stenting with Taxus Liberté stent: results from the OLYMPIA Registry (TAXUS Liberté Postapproval Global Program).
abstract: We evaluated the incidence of clinical events after implantation of the TAXUS Liberté paclitaxel-eluting stent in saphenous vein graft (SVG) lesions in an unselected patient population. The OLYMPIA (TAXUS Liberté Post-Approval Global Registry) program gathered data on 21 954 patients receiving at least 1 TAXUS Liberté stent, including 345 patients with SVG lesions. All cardiac events were monitored with independent adjudication of end points. Patients enrolled at procedure started with no mandated inclusion/exclusion criteria. In SVG-OLYMPIA (n = 345), baseline comorbidities/complex disease were more frequent than the rest of the OLYMPIA (n = 21 560). SVG-OLYMPIA had similar cardiac death, target vessel revascularization, and definitive stent thrombosis rates than the rest of OLYMPIA. Despite higher baseline risk, the SVG-OLYMPIA had similar 12-month clinical outcome than the rest of the OLYMPIA registry, confirming the safety and efficacy of the TAXUS Liberté stent in this high-risk group.
authors.affiliation: Hospital Universitario, Fundación Favaloro, Buenos Aires, Argentina. omendiz@ffavaloro.org
authors.forename: Oscar A
authors.initials: OA
authors.lastname: Mendiz
authors.forename: Waqar H
authors.initials: WH
authors.lastname: Ahmed
authors.forename: Carlos M
authors.initials: CM
authors.lastname: Fava
authors.forename: Jürgen
authors.initials: J
authors.lastname: vom Dahl
authors.forename: León R
authors.initials: LR
authors.lastname: Valdivieso
authors.forename: Gustavo A
authors.initials: GA
authors.lastname: Lev
authors.forename: Martyn
authors.initials: M
authors.lastname: R Thomas
mesh_terms: D000368:Aged; D017023:Coronary Angiography; D001026:Coronary Artery Bypass / Q000379:methods; D003324:Coronary Artery Disease / Q000601:surgery*; D054855:Drug-Eluting Stents / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D011474:Prosthesis Design; D012042:Registries; D012501:Saphenous Vein / Q000637:transplantation*; D016896:Treatment Outcome
chemical_list: D017239:Paclitaxel